...
search icon
celc-img

Celcuity LLC, Common Stock

CELC

NAQ

$12.11

-$0.45

(-3.58%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$494.16M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
115.43K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.39
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$7.58 L
$19.77 H
$12.11

About Celcuity LLC, Common Stock

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). It also engages in developing of CELsignia diagnostic platform. The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is based in Minneapolis, Minnesota. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameCELCSectorS&P500
1-Week Return-7.2%1.81%0.78%
1-Month Return11.92%3.75%2.88%
3-Month Return20.74%-4.88%9.45%
6-Month Return-3.27%-2.96%-0.12%
1-Year Return-21.06%-6.25%11.31%
3-Year Return58.3%12.43%61.11%
5-Year Return39.68%39.86%96.65%
10-Year Return-15.26%83.56%189.61%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue385.59K303.24K210.92K142.77K129.95K[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":78.64,"profit":true},{"date":"2022-12-31","value":54.7,"profit":true},{"date":"2023-12-31","value":37.03,"profit":true},{"date":"2024-12-31","value":33.7,"profit":true}]
Gross Profit(385.59K)(303.24K)(210.92K)(142.77K)-[{"date":"2020-12-31","value":-38559100,"profit":false},{"date":"2021-12-31","value":-30323500,"profit":false},{"date":"2022-12-31","value":-21091800,"profit":false},{"date":"2023-12-31","value":-14277200,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Gross Margin(Infinity%)(Infinity%)(Infinity%)(Infinity%)-[{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses9.56M28.36M39.39M66.09M113.27M[{"date":"2020-12-31","value":8.44,"profit":true},{"date":"2021-12-31","value":25.03,"profit":true},{"date":"2022-12-31","value":34.78,"profit":true},{"date":"2023-12-31","value":58.35,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(9.56M)(28.36M)(39.39M)(66.23M)(113.27M)[{"date":"2020-12-31","value":-955616400,"profit":false},{"date":"2021-12-31","value":-2835591500,"profit":false},{"date":"2022-12-31","value":-3939109100,"profit":false},{"date":"2023-12-31","value":-6623033100,"profit":false},{"date":"2024-12-31","value":-11326695100,"profit":false}]
Total Non-Operating Income/Expense163.98K(2.50M)(1.96M)4.08M2.98M[{"date":"2020-12-31","value":4.02,"profit":true},{"date":"2021-12-31","value":-61.24,"profit":false},{"date":"2022-12-31","value":-47.99,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":72.94,"profit":true}]
Pre-Tax Income(9.47M)(29.61M)(40.37M)(63.78M)(111.78M)[{"date":"2020-12-31","value":-947417500,"profit":false},{"date":"2021-12-31","value":-2960526600,"profit":false},{"date":"2022-12-31","value":-4037004000,"profit":false},{"date":"2023-12-31","value":-6377911600,"profit":false},{"date":"2024-12-31","value":-11177910500,"profit":false}]
Income Taxes(385.47K)959.12K978.95K(3.00)-[{"date":"2020-12-31","value":-39.38,"profit":false},{"date":"2021-12-31","value":97.97,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(9.09M)(30.56M)(41.35M)(63.78M)-[{"date":"2020-12-31","value":-908870400,"profit":false},{"date":"2021-12-31","value":-3056438100,"profit":false},{"date":"2022-12-31","value":-4134898900,"profit":false},{"date":"2023-12-31","value":-6377911300,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(9.47M)(29.61M)(40.37M)(56.51M)(111.78M)[{"date":"2020-12-31","value":-947417500,"profit":false},{"date":"2021-12-31","value":-2960526600,"profit":false},{"date":"2022-12-31","value":-4037004000,"profit":false},{"date":"2023-12-31","value":-5651199000,"profit":false},{"date":"2024-12-31","value":-11177910500,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(9.09M)(30.56M)(41.35M)(63.78M)(111.78M)[{"date":"2020-12-31","value":-908870400,"profit":false},{"date":"2021-12-31","value":-3056438100,"profit":false},{"date":"2022-12-31","value":-4134898900,"profit":false},{"date":"2023-12-31","value":-6377911600,"profit":false},{"date":"2024-12-31","value":-11177910500,"profit":false}]
EPS (Diluted)(0.75)(1.79)(2.62)(2.69)(2.66)[{"date":"2020-12-31","value":-75,"profit":false},{"date":"2021-12-31","value":-179,"profit":false},{"date":"2022-12-31","value":-262,"profit":false},{"date":"2023-12-31","value":-269,"profit":false},{"date":"2024-12-31","value":-266,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

CELC
Cash Ratio 0.50
Current Ratio 6.61

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CELC
ROA (LTM) -39.04%
ROE (LTM) -115.39%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CELC
Debt Ratio Lower is generally better. Negative is bad. 0.60
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.40

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CELC
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 5.46
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Celcuity LLC share price today?

Celcuity LLC (CELC) share price today is $12.11

Can Indians buy Celcuity LLC shares?

Yes, Indians can buy shares of Celcuity LLC (CELC) on Vested. To buy Celcuity LLC from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CELC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Celcuity LLC be purchased?

Yes, you can purchase fractional shares of Celcuity LLC (CELC) via the Vested app. You can start investing in Celcuity LLC (CELC) with a minimum investment of $1.

How to invest in Celcuity LLC shares from India?

You can invest in shares of Celcuity LLC (CELC) via Vested in three simple steps:

  • Click on Sign Up or Invest in CELC stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Celcuity LLC shares
What is Celcuity LLC 52-week high and low stock price?

The 52-week high price of Celcuity LLC (CELC) is $19.77. The 52-week low price of Celcuity LLC (CELC) is $7.58.

What is Celcuity LLC price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Celcuity LLC (CELC) is 5.46

What is the Market Cap of Celcuity LLC?

The market capitalization of Celcuity LLC (CELC) is $494.16M

What is Celcuity LLC’s stock symbol?

The stock symbol (or ticker) of Celcuity LLC is CELC

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top